webinar register page

Topic

2022 International Day of Immunology - Science, State and Challenges of COVID-19 vaccines

Description

Agenda:

| Welcome - Faith Osier (UK) and Federica Sallusto (Switzerland)
| Opening lecture: Landscape of COVID-19 vaccines - Dr. Seth Berkley (Switzerland)
| Act early and at the right place: kinetic and localization of SARS-CoV-2 specific T cells after infection and vaccination - Antonio Bertoletti (Singapore)
| The role of memory B cells in COVID-1 infection and vaccination - Rita Carsetti (Italy)
| NK cell responses across the COVID-19 disease spectrum - Andreas Diefenbach (Germany)
| Immunology of Long COVID - Akiko Iwasaki (USA)

| Break / Video

| Panel session: Current State, Challenges and Prospects of COVID-19 vaccines
- Apoorva Mandavilli (USA)
- Ridha Barbouche (Tunisia)
- Emma Hodcroft (Switzerland)
- Florian Krammer (USA)
- Herbert (Skip) Virgin (USA)

Time

Apr 29, 2022 03:00 PM in Amsterdam, Berlin, Rome, Stockholm, Vienna

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: .

All fields are required

Your Information
Send to
Message preview	Hi there, You are invited to a Zoom webinar. When: Apr 29, 2022 03:00 PM Amsterdam, Berlin, Rome, Stockholm, Vienna Topic: 2022 International Day of Immunology - Science, State and Challenges of COVID-19 vaccines Register in advance for this webinar: https://zoom.us/webinar/register/WN_v8sK7SNgTOevCubIvqWx_Q After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers Seth Berkley (Switzerland) (Speaker ) A pioneer in global public health for more than 35 years, Dr Seth Berkley has been a champion of equitable access to vaccines and of innovation, and a driving force to improve the way the world prevents and responds to infectious disease. A medical doctor and infectious disease epidemiologist, Dr Berkley joined Gavi, the Vaccine Alliance as its CEO in August 2011. Under his leadership, Gavi has accelerated global immunisation access in its mission to save lives, reduce poverty and protect the world against the threat of epidemics and pandemics. During his tenure, Gavi has increased coverage of routine immunisation in lower-income countries: even during the COVID-19 pandemic, Gavi helps protect nearly half the world’s children, vaccinating more than 888 million children in just over two decades, reducing vaccine-preventable child deaths by 70% and preventing more than 15 million future deaths. Antonio Bertoletti (Singapore) (Speaker ) Antonio Bertoletti trained as a specialist in infectious diseases at the Scripps Research Institute, US, and the University of Parma, Italy, where he was the first to characterize hepatitis B virus (HBV)-specific CD8+ T cells. Subsequently, he moved to University College of London in 1997 where he pioneered the use of HLA-tetramers to characterize the role of HBV-specific T cells in viral control and disease pathogenesis. In 2006, he became the Director of the Infection and Immunity Program at A*STAR’s Singapore Institute for Clinical Sciences before joining Duke-NUS Medical School in 2013. Rita Carsetti (Italy) (Speaker ) Rita Carsetti is the Head of the B cell pathophysiology Research Unit of the Bambino Gesù Children Hospital IRCCS in Rome. In the last years, she has been involved in several projects related to the development of the immune system in children and adults and the changes due to different types of immunodeficiency. She is also involved in increasing the knowledge and public awareness on vaccines and vaccination and collaborates with patient associations. She is a founding member of the European B cell network and is the chair of the PUB committee of the IUIS. Andreas Diefenbach (Germany) (Speaker ) Andreas Diefenbach is Professor and Chair of Microbiology at Charité Berlin. His lab is particularly interested in understanding how the tissue-resident immune system coordinates adaptation of multicellular organisms to their environments (e.g., microbiota, nutrients). He graduated in Microbiology and Immunology (1998) from the University of Erlangen and obtained postdoctoral training at the Department of Molecular and Cellular Biology, University of California Berkeley (1999-2002). Prior to joining Charité, he led the Institute of Medical Microbiology at the Johannes-Gutenberg-University Mainz (2013-2016). Before, he was an Assistant Professor at the Skirball Institute of Biomolecular Medicine, New York University (2003-2006) and a Full Professor at the University of Freiburg (2006-2013). As a Physician Scientist, Andreas won grant support by the Howard Hughes Medical Institute, by the European Research Council, and by the Deutsche Forschungsgemeinschaft (DFG). Akiko Iwasaki (USA) (Speaker ) Akiko Iwasaki, PhD, is the Sterling Professor of Immunobiology and Molecular, Cellular, and Developmental Biology at Yale University, and Investigator of Howard Hughes Medical Institute. She received her PhD from University of Toronto in Canada and her postdoctoral training from National Institutes of Health. Her research focuses on mechanisms of immune defense against viruses at the mucosal surfaces. She is Lead Investigator of the Yale COVID-19 Recovery Study, which aims to determine the changes in immune response of people with long COVID after vaccination. Dr. Iwasaki also leads multiple other studies to interrogate the pathobiology of long COVID. Apoorva Mandavilli (USA) (Moderator ) Apoorva Mandavilli is a reporter for The New York Times, focusing on science and global health. She currently covers the coronavirus pandemic, vaccinations, the World Health Organization, Centers for Disease Control and Prevention and the Food and Drug Administration. She is the 2019 winner of the Victor Cohn Prize for Excellence in Medical Science Reporting. She is the founding editor in chief of Spectrum, an award-winning news site on autism science that grew an audience of millions. She led the team there for 13 years. She joined The Times in May 2020, after two years as a regular contributor. Emma Hodcroft (Switzerland) (Panelist ) Dr Emma B Hodcroft is formally a biologist, with a BSc from Texas Christian University in Biology – but she has been programming since at 15. After completing her MSc & PhD at the University of Edinburgh, studying evolution, population genetics, & phylogenetics in HIV, she worked as part of the Bill & Melinda Gates Foundation PANGEA-1 project, creating an agent-based model to simulate genetic data for HIV in African communities, in order to evaluate phylogenetic analyses methods. In 2017, she came to the University of Basel and began working as part of the Nextstrian team, where she helps both with programming, maintaining, and implementing new features and doing phylogenetic analyses. Until the COVID-19 crisis, Dr Hodcroft was studying Enterovirus-D68, a pathogen that causes serious respiratory illness and sometimes paralysis in young children, and had uncovered the potential for undetected transmission in adults as a source for childhood infections. Mohamed Ridha Barbouche (Tunisia) (Panelist ) Mohamed Ridha Barbouche is Professor of Immunology and Assistant-Dean Research at the Medical School, University of Tunis El-Manar. He is head of the Clinical Immunology Department and Director of a Research Laboratory at the Institut Pasteur de Tunis, Tunisia. He received his M.D. from the University of Tunis and his Ph.D. from the University Pierre et Marie Curie in Paris, France. He trained at the Institut Pasteur and Hôpital Necker-Enfants Malades in Paris. He was post-doctoral fellow at Cornell University in New York. His clinical activity interests are focused on the advanced immunological and genetic investigation as well as the care and genetic counseling for primary immune-deficiencies’ patients. His research activity is dedicated to the study of the molecular basis of these primary immune-deficiencies as a model for the study of genetic susceptibility to infections and immune-mediated diseases in humans. Florian Krammer (USA) (Panelist ) Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna (Austria) in 2010. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines. In 2014 he became an independent principal investigator and is currently the Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, flaviviruses, hantaviruses, filoviruses and arenaviruses. He has published more than 300 papers on these topics. Herbert “Skip” Virgin (USA) (Panelist ) Herbert “Skip” Virgin, MD, PhD, is the Executive Vice President of Research and Chief Scientific Officer at Vir Biotechnology. At Vir Dr. Virgin leads research into SARS-CoV2 monoclonal antibodies including sotrovimab, small molecules, and vaccines. He was previously Mallinckrodt Professor and Chair of the Department of Pathology & Immunology at Washington University School of Medicine in St. Louis. He received his MD and PhD degrees from Harvard University and trained in medicine at Boston’s Brigham and Women’s Hospital and infectious diseases at Barnes Jewish Hospital in St. Louis. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Academy of Microbiology, the National Academy of Sciences and is on the Editorial Boards of Cell Host and Microbe. During his time at Washington University, Dr. Virgin’s Lab defined mechanisms of viral pathogenesis and immunity in vivo.

Time Zone:

webinar register page

Share via Email

Switch Time Zone

Upcoming Meetings